Toll-like receptor-9 is involved in the development of B cell stimulating factor-induced systemic lupus erythematosus

  • Authors:
    • Ying Liu
    • Feng Zhan
    • Xiao Zhang
    • Shudian Lin
  • View Affiliations

  • Published online on: October 31, 2017     https://doi.org/10.3892/etm.2017.5411
  • Pages: 585-591
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The objective of the present study was to investigate the role of Toll‑like receptor (TLR)‑9 in B lymphocyte stimulating factor (BLyS)‑induced systemic lupus erythematosus (SLE) in mice. The anti‑double stranded (ds)DNA antibody titer, levels of complement proteins (C3 and C4), interleukin (IL)‑10 and the disease activity [assessed by the erythrocyte sedimentation rate (ESR) and C‑reactive protein (CRP) level] were measured. A total of 21 transgenic female mice (aged 8‑10 weeks and weighing 30‑40 g) expressing the Epstein‑Barr virus membrane antigen, BLLF1, were studied. Mice were randomly divided into the control, the BLyS inhibition and the TLR‑9 inhibition groups, with 7 mice in each group. Mice in the blank control group received intraperitoneal injections of normal saline, mice in the BLyS inhibition group received intraperitoneal injections of anti‑BR3 monoclonal antibody (5,000 ng/day) and mice in the TLR‑9 inhibition group received intraperitoneal injections of anti‑human TLR‑9 antibody (250 ng/day). The treatment regimens continued for 10 days, followed by the collection of peripheral venous blood. The relative levels of TLR‑9 mRNA were measured by reverse transcription‑quantitative polymerase chain reaction. Furthermore, the BLyS protein concentration and IL‑10 levels were measured by ELISA. TLR‑9 mRNA, BLyS, IL‑10, anti‑dsDNA antibody titer, C3, C4, ESR and CRP levels of the blank control group were significantly higher than those of the other two groups (P<0.05). The differences in comparison of these indexes between the BLyS inhibition and TLR‑9 inhibition groups were not statistically significant (P>0.05), with the exception of TLR‑9 mRNA and BLyS. In conclusion, the TLR‑9 signaling pathway may be important for BLyS‑induced SLE, and regulation of the inflammatory immune level.
View Figures
View References

Related Articles

Journal Cover

January-2018
Volume 15 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu Y, Zhan F, Zhang X and Lin S: Toll-like receptor-9 is involved in the development of B cell stimulating factor-induced systemic lupus erythematosus. Exp Ther Med 15: 585-591, 2018
APA
Liu, Y., Zhan, F., Zhang, X., & Lin, S. (2018). Toll-like receptor-9 is involved in the development of B cell stimulating factor-induced systemic lupus erythematosus. Experimental and Therapeutic Medicine, 15, 585-591. https://doi.org/10.3892/etm.2017.5411
MLA
Liu, Y., Zhan, F., Zhang, X., Lin, S."Toll-like receptor-9 is involved in the development of B cell stimulating factor-induced systemic lupus erythematosus". Experimental and Therapeutic Medicine 15.1 (2018): 585-591.
Chicago
Liu, Y., Zhan, F., Zhang, X., Lin, S."Toll-like receptor-9 is involved in the development of B cell stimulating factor-induced systemic lupus erythematosus". Experimental and Therapeutic Medicine 15, no. 1 (2018): 585-591. https://doi.org/10.3892/etm.2017.5411